Clinical Trial Update: Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ofatumumab in relapsed or progressive diffuse large B-cell lymphoma patients who are transplant-ineligible or relapsed after transpla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lymphoma, Large-Cell, Diffuse | Phase 2 | Status: COMPLETED | Results posted: 2011-09-08